Selexis Sa is a global Contract Development and Manufacturing Organization (CDMO) that specializes in providing innovative biologic solutions. They offer a wide range of services, including mammalian and microbial cell line development, process development, analytical development, formulation development, and clinical and commercial manufacturing. With their science-driven approach and customer-focused mindset, Selexis Sa is dedicated to driving breakthroughs in biopharmaceutical development and manufacturing to positively impact the lives of patients worldwide.
KBI Biopharma, operating as one organization with Selexis, is redefining the standards of contract development and manufacturing services for new biologics. They offer versatile, scalable, and efficient solutions, including their SUREtechnology Platform powered by Selexis for premium CHO-based cell line development, as well as the KBI PUREplatform for clean and efficient E. Coli expression. With comprehensive services in cell line development, process development, analytical development, formulation development, and clinical and commercial manufacturing, KBI Biopharma is committed to delivering exceptional quality and supporting the development and manufacturing of new biopharmaceuticals.
Generated from the website